Nasophoryngeal carcinomas and Epstein-Barr virus: From epidemiology and detection to therapy;Carcinomes nasopharyngés associés au virus d'Epstein-Barr: De l'épidémiologie à la thérapeutique et au dépistage

Medecine/Sciences

Volumn 20, Issue 4, 2004, Pages 453-457

  Busson, Pierre ^a   Ooka, Tadamassa ^b   Corbex, Marilys ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ DE LYON   (France)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; ONCOPROTEIN; VIRUS PROTEIN;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CHROMOSOME 3P; CHROMOSOME 4P; CHROMOSOME 5P; CLINICAL RESEARCH; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; GENE INACTIVATION; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; NONHUMAN; REVIEW; TUMOR SUPPRESSOR GENE; VIROLOGY; VIRUS CARCINOGENESIS; VIRUS DETECTION;

HUMAN HERPESVIRUS 4;

EID: 1842632666     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2004204453     Document Type: Review

References (26)

1. Yu MC, Yuan JM. Epidemiology of nasophoryngeal carcinoma. Semin Cancer Biol 2002; 12: 421-9.
2. Jeannel D, Hubert A, de Vathaire F, et al. Diet, living conditions and nasopharyngeal carcinoma in Tunisia - a case-control study. Int J Cancer 1990; 46: 421-5.
3. Laouamri S, Hamdi-Cherif M, Sekfali N, et al. Facteurs de risque alimentaires du carcinome du nasapharynx dans la région de Sétif (Algérie). Rev Epidemiol Sante Publique 2001; 49: 145-56.
4. Feng BJ, Huang W, Shugart YY, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002; 31: 395-9.
5. Makni-Baizig N, Ayed K, Ayed FB, et al. Association between HLA-A/-B antigens and -DRB1 alleles and nasopharyngeal carcinoma in Tunisia. Oncology 2001; 61: 55-8.
6. Dardari R, Khyatti M, Jauhadi H, et al. Study of human leukocyte antigen class I phenotypes in Moroccan patients with nasopharyngeal carcinoma. Int J Cancer 2001; 92: 294-7.
7. Sitki-Green D, Cavington M, Raab-Traub N. Compartmentalization and transmission of multiple Epstein-Barr virus strains in asymptomatic carriers. J Virol 2003; 77: 1840-7.
8. Nicholls J, Hahn P, Kremmer E, et al. Detection of wild type and deleted latent membrane protein 1 (LMP1) of Epstein-Barr virus in clinical biopsy material. J Virol Methods 2004; 116: 79-88.
9. Edwards RH, Sitki-Green D, Moare DT, Raab-Traub N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. J Virol 2004; 78: 868-81.
10. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003; 63: 8293-301.
11. Murono S, Inoue H, Tanabe T, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001; 98: 6905-10.
12. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J 2002; 21: 954-65.
13. Tsimbouri P, Drotar ME, Coy JL, Wilson JB. Bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene 2002; 21: 5182-7.
14. Khabir A, Ghorbel A, Daoud J, et al. Similar BCL-X but different BCL-2 levels in the two age groups of North African nasopharyngeal carcinomas. Cancer Detect Prev 2003; 27: 250-5.
15. Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, et al. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 2000; 60: 5584-8.
16. Gulley ML, Nicholls JM, Schneider BG, et al. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 1998; 152: 865-9.
17. Ablashi D, Bornkamm GW, Boshoff C, et al. Proceedings of the IARC Working Group on the evaluation of carcinogenic risks to humans. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. Lyon, France, 17-24 June 1997. IARC Monagr Eval Carcinog Risks Hum 1997; 70: 1-492.
18. Dardari R, Hinderer W, Lang D, et al. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. J Clin Microbiol 2001, 39: 3164-70.
19. Chan KCA, Lo YMD. Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 489-96.
20. Liu HX, Ding YQ, Li X, Yao KT. Investigation of Epstein-Barr virus in Chinese colorectal tumors. World J Gastroenterol 2003; 9: 2464-8.
21. Shimakage M, Kawahara K, Sasagawa T, et al. Expression of Epstein-Barr virus in thyroid carcinoma correlates with tumor progression. Hum Pathol 2003; 34: 1170-7.
22. Zur Hausen A, Brink AA, Craanen ME, et al. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 2000; 60: 2745-8.
23. Huang J, Chen H, Hutt-Fletcher L, et al. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol 2003; 77: 13267-74.
24. Feng WH, Israel B, Raab-Traub N, et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002; 62: 1920-6.
25. Li JH, Shi W, Chia M, et al. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mal Ther 2003; 8: 964-73.
26. o 5. Lyon: IARC Press, 2001.